A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
12/2002
12/19/2002	US20020193288 Methods of treating hypertension and compositions for use therein
12/19/2002	US20020192826 Recombinant AAV vector-based transduction system and use of same
12/19/2002	US20020192760 Nucleotide sequences coding membrane protein for use the diagnosis and treatment of asthma, parkinson's, heart defects, hypotension, urogenital disorders
12/19/2002	US20020192758 C3b/C4b complement receptor-like molecules and uses thereof
12/19/2002	US20020192749 Human polynucleotides, polypeptides, and antibodies
12/19/2002	US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002	US20020192681 Detection of parasite in sample; obtain sample, isolate nucleotide sequences from dendritic cells, determine gene expression, presence of preferential gene indicates infections
12/19/2002	US20020192644 Detection of natural killer receptor; obtain samples, incubate with oligonucleotides, detect bound complexes, presence of complexes indicates receptor
12/19/2002	US20020192643 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferation or inflammatory disorders
12/19/2002	US20020192638 Evaluation of cells sensitvity to anticancer agents; obtain tissue, separate, culture tissue, inoculate cells, incubate with anticancer agent, monitor sensitivity to anticancer agents
12/19/2002	US20020192312 Pharmaceutical compositions
12/19/2002	US20020192285 Controlled release pellet formulation
12/19/2002	US20020192216 Therapeutic use
12/19/2002	US20020192205 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
12/19/2002	US20020192199 Composition and methods for enhanced tumor cell immunity in vivo
12/19/2002	US20020192195 Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
12/19/2002	US20020192193 Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/19/2002	US20020192192 Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/19/2002	US20020192157 Treatment and diagnosis of macrophage mediated disease
12/19/2002	DE10127712A1 Use of immunoglobulin M for treatment and prevention of systemic lupus erythematosus, administered subcutaneously or intramuscularly
12/19/2002	CA2450285A1 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/19/2002	CA2450269A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	CA2450265A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449941A1 Use of radiopharmaceutical complexes in achieving transplantation tolerance
12/19/2002	CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002	CA2449544A1 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002	CA2449517A1 Tissue-specific endothelial membrane proteins
12/19/2002	CA2449272A1 Intracellular signaling molecules
12/19/2002	CA2449247A1 A method for treating inflammatory diseases by administering a ppar-delta agonist
12/19/2002	CA2449213A1 Ophthalmic compositions comprising hyaluronic acid
12/19/2002	CA2447687A1 Substituted 1-benzazepines and derivatives thereof
12/19/2002	CA2445605A1 Treatment or prophylaxis of insulin-producing cell graft rejection
12/18/2002	EP1266965A2 Recombinant antibodies for human therapy
12/18/2002	EP1266899A2 Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them
12/18/2002	EP1266663A1 Eosinophil-specific apoptosis inducer
12/18/2002	EP1266014A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
12/18/2002	EP1266012A2 Proteases
12/18/2002	EP1266008A2 Acute neuronal induced calcium binding protein type 1 ligand
12/18/2002	EP1266005A2 Regulation of human lipoxin a4 receptor-like protein
12/18/2002	EP1266002A2 Il-17 receptor like molecules and uses thereof
12/18/2002	EP1266001A2 Human transcription factors
12/18/2002	EP1265989A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
12/18/2002	EP1265924A2 Il-17 receptor like molecules and uses thereof
12/18/2002	EP1265919A2 G-protein associated molecules
12/18/2002	EP1265918A1 Human immune response proteins
12/18/2002	EP1265916A2 Therapeutic anti-cytomegalovirus compounds
12/18/2002	EP1265913A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
12/18/2002	EP1265905A1 Il-8 receptor antagonists
12/18/2002	EP1265903A1 Thiepino[3,2-b]dihydropyridines and related compositions and methods
12/18/2002	EP1265900A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
12/18/2002	EP1265899A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/18/2002	EP1265891A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
12/18/2002	EP1265870A1 New ccr5 modulators: benzimidazoles or benzotriazoles
12/18/2002	EP1265863A1 Heterocyclic side chain containing metalloprotease inhibitors
12/18/2002	EP1265862A2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
12/18/2002	EP1265860A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
12/18/2002	EP1265859A2 Amidino compounds useful as nitric oxide synthase inhibitors
12/18/2002	EP1265855A1 Novel cd23 inhibitors
12/18/2002	EP1265853A1 Carboxylic acid derivatives as ip antagonists
12/18/2002	EP1265848A2 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
12/18/2002	EP1265840A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
12/18/2002	EP1265839A1 Compounds active at the glucocorticoid receptor
12/18/2002	EP1265648A1 Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such
12/18/2002	EP1265633A2 Adjuvant for vaccines
12/18/2002	EP1265632A2 Lipopeptide adjuvants
12/18/2002	EP1265631A1 Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant
12/18/2002	EP1265630A2 Use of insulin for the treatment of cartilagenous disorders
12/18/2002	EP1265616A2 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
12/18/2002	EP1265615A2 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
12/18/2002	EP1265606A1 Cell adhesion inhibitors
12/18/2002	EP1265603A2 Il-8 receptor antagonists
12/18/2002	EP1265598A1 Pharmaceutical composition for application to mucosal surfaces
12/18/2002	EP1265595A2 Stabilized ascorbic acid solutions
12/18/2002	EP1104420B1 Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
12/18/2002	EP1098898B1 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate
12/18/2002	EP1086101B1 Beta-carboline compounds
12/18/2002	EP0934300B1 The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
12/18/2002	EP0930887B1 Cancer immunotherapy using tumor cells combined with mixed lymphocytes
12/18/2002	EP0882038B1 substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
12/18/2002	EP0880526B1 Heterocycle-condensed morphinoid derivatives (ii)
12/18/2002	EP0859784B1 Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
12/18/2002	EP0788792B1 Matrix type patch preparation
12/18/2002	EP0760668B1 Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases
12/18/2002	EP0650357B1 Rapamycin derivatives
12/18/2002	EP0630255B1 Mhc conjugates useful in ameliorating autoimmunity
12/18/2002	EP0551440B1 Design of bioactive peptides based on immunoglobulin structure
12/18/2002	CN1385528A Live vaccine for treating anaphylaxis
12/18/2002	CN1385204A Antianaphylactic Chinese medicine preparation
12/18/2002	CN1385200A Lily bulb health care product
12/18/2002	CN1096460C Novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for treatment of allergic diseases
12/17/2002	US6495735 Transgenic non-human mammals expressing DNA sequences encoding homologous complement restriction factors of a discordant mammalian species
12/17/2002	US6495687 Adenosine receptors are involved in a vast number of peripheral and central regulatory mechanisms such as, for example, vasodilation, cardiac depression, inhibition of lipolysis, inhibition of insulin release and potentiation
12/17/2002	US6495677 Nucleoside compounds
12/17/2002	US6495606 Administering s-((r)-2-(1-iminoethylamino)propyl)-l-cysteine
12/17/2002	US6495604 Cycloalkene derivatives, process for producing the same, and use
12/17/2002	US6495589 An amino acid derivative useful to increase secretion of growth hormone (gh) from the anterior pituitary of mammals, including on sustained release basis
12/17/2002	US6495585 Method for treating hyperproliferative tissue in a mammal
12/17/2002	US6495582 Erk (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease

1 ... 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 ... 1172